Published in AIDS on February 14, 2003
Human herpesvirus 8--a novel human pathogen. Virol J (2005) 1.00
Seroprevalence and risk factors for human herpesvirus 8 infection, rural Egypt. Emerg Infect Dis (2008) 0.92
Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China. Clin Microbiol Infect (2011) 0.85
Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med (2004) 0.83
The Zambia Children's KS-HHV8 Study: rationale, study design, and study methods. Am J Epidemiol (2011) 0.82
Seroprevalence of human herpesvirus 8 and hepatitis C virus among drug users in Shanghai, China. Viruses (2014) 0.78
Human herpesvirus 8 seroprevalence among Tobago women and the role of sexual lifestyle behavior. J Med Virol (2009) 0.77
Massive vulval Kaposi's sarcoma in pregnancy: case report. Int Med Case Rep J (2016) 0.75
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV. Eur J Epidemiol (2004) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
A potential decline in life expectancy in the United States in the 21st century. N Engl J Med (2005) 19.63
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Identification of severe acute respiratory syndrome in Canada. N Engl J Med (2003) 14.29
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 8.19
Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr (2002) 7.79
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med (2010) 3.81
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med (2002) 3.39
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med (2002) 3.31
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr (2010) 2.96
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis (2005) 2.59
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics. Proc Natl Acad Sci U S A (2010) 2.43
Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis (2003) 2.42
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 2.29
Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med (2010) 2.28
Electrical propagation in synthetic ventricular myocyte strands from germline connexin43 knockout mice. Circ Res (2004) 2.25
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol (2003) 2.20
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr (2010) 2.19
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19
Conservation of virally encoded microRNAs in Kaposi sarcoma--associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. J Infect Dis (2007) 2.17
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
SARS among critical care nurses, Toronto. Emerg Infect Dis (2004) 2.10
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS (2008) 1.99
Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ Res (2006) 1.97
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine (2006) 1.97
Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr (2011) 1.96
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS (2004) 1.94
Severe group a streptococcal soft-tissue infections in Ontario: 1992-1996. Clin Infect Dis (2002) 1.93
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis (2007) 1.88
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA (2005) 1.86
Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr (2005) 1.84
Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis (2006) 1.83
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol (2007) 1.82
Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology (2006) 1.81
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics (2006) 1.78
Illness in intensive care staff after brief exposure to severe acute respiratory syndrome. Emerg Infect Dis (2003) 1.76
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74